Oppenheimer Comments On Express Scripts Following 3Q14 Results
In a research report issued today, Oppenheimer analyst Bret Jones maintained an Outperform rating on Express Scripts (NASDAQ:ESRX) with a price target of $82, following the company’s third-quarter earnings, posting EPS that was in line with the Street.
Jones said, “With gross profit per Rx only down a penny sequentially, we accept management’s explanation that investments in service improvements drove the softer EBITDA/Rx metric. We continue to believe the shares’ valuation more than accounts for the modest margin deterioration in the quarter, especially if management can link the service investments to a normalization of the retention rate on this morning’s conference call.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Bret Jones has a total average return of 0.6% and a 54.5% success rate. Jones has a 11.9% average return when recommending ESRX, and is ranked #2072 out of 3350 analysts.